In this study we first tested the concept of treating with a MEK inhibitor upon progression on a BRAF inhibitor in selected melanoma cell lines that encompassed cell lines with primarily resistance to vemurafenib, those with acquired resistance to vemurafenib after in vitro exposure, and those established from patient-derived biopsies progressing after vemurafenib. The gene discussed is MAP2K7; the disease is melanoma.